JP6668379B2 - 褐色脂肪組織を活性化する際に神経を阻害するための方法及び装置 - Google Patents
褐色脂肪組織を活性化する際に神経を阻害するための方法及び装置 Download PDFInfo
- Publication number
- JP6668379B2 JP6668379B2 JP2017553044A JP2017553044A JP6668379B2 JP 6668379 B2 JP6668379 B2 JP 6668379B2 JP 2017553044 A JP2017553044 A JP 2017553044A JP 2017553044 A JP2017553044 A JP 2017553044A JP 6668379 B2 JP6668379 B2 JP 6668379B2
- Authority
- JP
- Japan
- Prior art keywords
- bat
- nerve
- electrical signal
- patient
- nerves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003486 adipose tissue brown Anatomy 0.000 title claims description 237
- 210000005036 nerve Anatomy 0.000 title claims description 160
- 238000000034 method Methods 0.000 title description 61
- 230000003213 activating effect Effects 0.000 title description 33
- 230000002401 inhibitory effect Effects 0.000 title description 10
- 238000009825 accumulation Methods 0.000 claims description 61
- 230000004913 activation Effects 0.000 claims description 42
- 230000002889 sympathetic effect Effects 0.000 claims description 42
- 210000005037 parasympathetic nerve Anatomy 0.000 claims description 32
- 230000001953 sensory effect Effects 0.000 claims description 19
- 230000001537 neural effect Effects 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 9
- 238000005265 energy consumption Methods 0.000 claims description 8
- 230000036982 action potential Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 4
- 230000035508 accumulation Effects 0.000 description 60
- 239000002858 neurotransmitter agent Substances 0.000 description 52
- 239000000126 substance Substances 0.000 description 47
- 238000001994 activation Methods 0.000 description 41
- 239000000835 fiber Substances 0.000 description 25
- 210000002820 sympathetic nervous system Anatomy 0.000 description 24
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 230000003227 neuromodulating effect Effects 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 18
- 230000004007 neuromodulation Effects 0.000 description 16
- 230000001734 parasympathetic effect Effects 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 12
- 210000001593 brown adipocyte Anatomy 0.000 description 12
- 210000000609 ganglia Anatomy 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- 208000016261 weight loss Diseases 0.000 description 10
- 230000004580 weight loss Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 8
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 8
- 210000000593 adipose tissue white Anatomy 0.000 description 8
- 210000003050 axon Anatomy 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 230000002999 depolarising effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 210000000225 synapse Anatomy 0.000 description 7
- 210000003403 autonomic nervous system Anatomy 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000007933 dermal patch Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- -1 etc.) Proteins 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000007383 nerve stimulation Effects 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002060 circadian Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000002102 hyperpolarization Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007682 sleeve gastrectomy Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 2
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000003766 afferent neuron Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 210000003715 limbic system Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000968 medical method and process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000005034 parasympathetic neuron Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 210000000331 sympathetic ganglia Anatomy 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000003868 tissue accumulation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 101100202237 Danio rerio rxrab gene Proteins 0.000 description 1
- 101100309320 Danio rerio rxrga gene Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101100390675 Mus musculus Fgf15 gene Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000001406 Perilipin Human genes 0.000 description 1
- 108060006002 Perilipin Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036410 Postoperative wound infection Diseases 0.000 description 1
- 101150050070 RXRA gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 239000004775 Tyvek Substances 0.000 description 1
- 229920000690 Tyvek Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004079 adrenergic fiber Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 210000003295 arcuate nucleus Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003198 cerebellar cortex Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003457 ganglion blocking agent Substances 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 230000000393 hypersympathetic effect Effects 0.000 description 1
- 210000000194 hypogastric plexus Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000002589 oculomotor nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008701 parasympathetic activation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 210000002466 splanchnic nerve Anatomy 0.000 description 1
- 210000004686 stellate ganglion Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0456—Specially adapted for transcutaneous electrical nerve stimulation [TENS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36034—Control systems specified by the stimulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Electrotherapy Devices (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Laser Surgery Devices (AREA)
Description
(1) 第1の神経調節因子を褐色脂肪組織(BAT)の蓄積部位(depot)に適用することであって、前記第1の神経調節因子の前記適用が前記BAT内の第1の神経タイプの活性化を引き起こすことで前記BATのエネルギー消費を増加させる、ことと、
前記第1の神経調節因子の前記適用と同時に前記BATの蓄積部位に第2の神経調節因子を適用することであって、前記第2の神経調節因子の前記適用が前記第1の神経タイプと異なる前記BAT内の第2の神経タイプを阻害する、ことと、を含む、医療方法。
(2) 前記第1の神経タイプが交感神経を含み、前記第2の神経タイプが副交感神経を含む、実施態様1に記載の方法。
(3) 前記第1の神経タイプが交感神経を含み、前記第2の神経タイプが知覚神経を含む、実施態様1に記載の方法。
(4) 前記第2の神経調節因子の前記適用が、前記第1の神経調節因子の前記適用が開始されるよりも前に開始されることで前記第1の神経タイプが活性化されるよりも前に前記第2の神経タイプの阻害が開始される、実施態様1に記載の方法。
(5) 前記第1の神経調節因子を適用することが、前記BATの蓄積部位に第1の電気信号を印加することを含み、前記第2の神経調節因子を適用することが、前記BATの蓄積部位に前記第1の電気信号とは異なる第2の電気信号を印加することを含む、実施態様1に記載の方法。
(7) 前記第1の神経調節因子を適用することが、前記BATの蓄積部位に第1の化学物質を送達することを含み、前記第2の神経調節因子を適用することが、前記BATの蓄積部位に前記第1の化学物質とは異なる第2の化学物質を送達することを含む、実施態様1に記載の方法。
(8) 前記第1の神経調節因子を適用することが、前記BATの蓄積部位に電気信号を印加すること、前記BATの蓄積部位に化学物質を送達すること、前記BATの蓄積部位を冷却すること、及び前記BATの蓄積部位に光を照射することのうちの少なくとも1つを含み、前記第2の神経調節因子を適用することが、前記BATの蓄積部位に異なる電気信号を印加すること、及び前記BATの蓄積部位に異なる化学物質を送達することのうちの少なくとも一方を含む、実施態様1に記載の方法。
(9) 患者の褐色脂肪組織(BAT)の蓄積部位に近接する患者の交感神経系を神経調節することで前記BATを活性化して前記BATのエネルギー消費を増加させることと、
前記交感神経系を前記神経調節することと同時に、前記褐色脂肪組織の蓄積部位に近接する前記患者の副交感神経系を抑制することと、を含む、医療方法。
(10) 前記交感神経系を神経調節することが、前記BATを神経支配している交感神経を活性化し、前記副交感神経系を抑制することが、前記BATを神経支配している副交感神経を抑制し、前記副交感神経の各々が前記交感神経の各々よりも大きい径を有する、実施態様9に記載の方法。
(12) 前記交感神経系を神経調節することが、前記患者に第1の電気信号を印加することを含む、実施態様9に記載の方法。
(13) 前記副交感神経系を抑制することが、前記患者に前記第1の電気信号とは異なる第2の電気信号を印加することを含む、実施態様11に記載の方法。
(14) 前記第1の電気信号の電流が、前記第2の電気信号の電流よりも10〜100倍大きい範囲にある、実施態様13に記載の方法。
(15) 前記第2の電気信号が、前記第1の電気信号と比較してより低エネルギーの過分極パルス、及び前記第1の電気信号と比較してより低エネルギーの脱分極パルスのうちの一方を含む、実施態様13に記載の方法。
(17) 前記交感神経系を神経調節することが、前記患者に第1の化学物質を投与することを含む、実施態様9に記載の方法。
(18) 前記副交感神経系を抑制することが、前記患者に前記第1の化学物質とは異なる第2の化学物質を投与すること、及び前記患者に電気信号を印加することのうちの一方を含む、実施態様17に記載の方法。
(19) 前記交感神経系を神経調節することが、前記患者に電気信号を印加すること、前記患者に化学物質を投与すること、前記患者を冷却すること、及び前記患者に光を照射することのうちの少なくとも1つを含む、実施態様9に記載の方法。
(20) 褐色脂肪組織(BAT)の蓄積部位に近接する患者の組織に直接接触するように、かつ前記患者に第1及び第2の電気信号を同時に供給するように構成された少なくとも1つの電極であって、前記第1の電気信号が前記BAT内の第1の神経タイプの活性化を引き起こすことで前記BATのエネルギー消費を増加させるように構成され、前記第2の電気信号が前記第1の神経タイプとは異なる前記BAT内の第2の神経タイプを阻害するように構成されている、少なくとも1つの電極と、
前記少なくとも1つの電極と電子通信しており、かつ前記少なくとも1つの電極により供給される前記第1及び第2の電気信号を発生するように構成された少なくとも1つの信号生成器と、を備える、医療器具。
Claims (1)
- 褐色脂肪組織(BAT)の蓄積部位に近接する患者の組織に直接接触するように、かつ前記患者に第1及び第2の電気信号を同時に供給するように構成された少なくとも1つの電極であって、前記第1の電気信号が前記BAT内の第1の神経タイプの活性化を引き起こすことで前記BATのエネルギー消費を増加させるように構成され、前記第2の電気信号が前記第1の神経タイプとは異なる前記BAT内の第2の神経タイプを阻害するように構成されている、少なくとも1つの電極と、
前記少なくとも1つの電極と電子通信しており、かつ前記少なくとも1つの電極により供給される前記第1及び第2の電気信号を発生するように構成された少なくとも1つの信号生成器と、を備え、
前記第1の神経タイプが交感神経であり、
前記第2の神経タイプが副交感神経又は知覚神経であり、
前記第1の電気信号が前記BATに印加される前に、前記第2の電気信号が前記BATに印加されることで、前記第2の神経タイプでの新たな活動電位形成を防止するように構成されている、医療器具。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/584,046 | 2014-12-29 | ||
US14/584,046 US10092738B2 (en) | 2014-12-29 | 2014-12-29 | Methods and devices for inhibiting nerves when activating brown adipose tissue |
PCT/US2015/065513 WO2016109169A1 (en) | 2014-12-29 | 2015-12-14 | Methods and devices for inhibiting nerves when activating brown adipose tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018501069A JP2018501069A (ja) | 2018-01-18 |
JP6668379B2 true JP6668379B2 (ja) | 2020-03-18 |
Family
ID=55236897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017553044A Active JP6668379B2 (ja) | 2014-12-29 | 2015-12-14 | 褐色脂肪組織を活性化する際に神経を阻害するための方法及び装置 |
Country Status (6)
Country | Link |
---|---|
US (3) | US10092738B2 (ja) |
EP (1) | EP3240606B1 (ja) |
JP (1) | JP6668379B2 (ja) |
CN (1) | CN107278161B (ja) |
BR (1) | BR112017013892B1 (ja) |
WO (1) | WO2016109169A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US11324673B2 (en) | 2016-11-18 | 2022-05-10 | Miraki Innovation Think Tank Llc | Cosmetic appearance of skin |
MX2019007714A (es) | 2016-12-27 | 2019-09-09 | Avent Inc | Articulo y metodo para tratar neuropatia diabetica periferica. |
AU2018226785A1 (en) * | 2017-03-01 | 2019-10-24 | Miraki Innovation Think Tank Llc | Cryotherapies |
KR102589816B1 (ko) | 2017-04-05 | 2023-10-16 | 미라키 이노베이션 씽크 탱크 엘엘씨 | 저온 슬러리 격납 |
WO2018187573A1 (en) | 2017-04-05 | 2018-10-11 | Arctic Fox Biomedical, Inc. | Point of delivery cold slurry generation |
US10500342B2 (en) | 2017-08-21 | 2019-12-10 | Miraki Innovation Think Tank Llc | Cold slurry syringe |
WO2019173518A1 (en) | 2018-03-09 | 2019-09-12 | General Electric Company | Neuromodulation techniques |
CA3098686A1 (en) * | 2018-04-29 | 2019-11-07 | Brian A. GANDEL | Device and method for inducing lypolysis in humans |
WO2023052947A1 (en) | 2021-09-29 | 2023-04-06 | Cilag Gmbh International | Surgical devices, systems, and methods for control of one visualization with another |
US20230100698A1 (en) * | 2021-09-29 | 2023-03-30 | Cilag Gmbh International | Methods for Controlling Cooperative Surgical Instruments |
WO2023052937A1 (en) | 2021-09-29 | 2023-04-06 | Cilag Gmbh International | Surgical system for altering the body's sensing of food |
WO2023052943A1 (en) | 2021-09-29 | 2023-04-06 | Cilag Gmbh International | Surgical devices, systems, and methods for control of one visualization with another |
WO2023052941A1 (en) | 2021-09-29 | 2023-04-06 | Cilag Gmbh International | Surgical system for delivering energy to tissue in an anatomic space and monitoring a tissue parameter in a different anatomic space |
WO2023052935A1 (en) | 2021-09-29 | 2023-04-06 | Cilag Gmbh International | Surgical devices, systems, and methods for control of one visualization with another |
EP4271295A1 (en) | 2021-09-29 | 2023-11-08 | Cilag GmbH International | Surgical devices, systems, and methods for control of one visualization with another |
Family Cites Families (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
US4498843A (en) | 1982-08-02 | 1985-02-12 | Schneider Philip H | Insulin infusion pump |
JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
GB8714901D0 (en) | 1986-07-23 | 1987-07-29 | Ici Plc | Amide derivatives |
US4978338A (en) | 1988-04-21 | 1990-12-18 | Therex Corp. | Implantable infusion apparatus |
CH676164A5 (ja) | 1988-05-28 | 1990-12-14 | Sc Techn Dipl Ing Peter A Neuk | |
CN2045308U (zh) | 1988-10-12 | 1989-10-04 | 路雪清 | 电子减肥机 |
CN2045380U (zh) | 1989-01-07 | 1989-10-04 | 苏州市制冷设备厂 | 氯气液化装置 |
DK339289D0 (da) | 1989-07-07 | 1989-07-07 | Dak Lab As | Farmaceutisk praeparat |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
GB9111426D0 (en) | 1991-05-28 | 1991-07-17 | Ici Plc | Chemical compounds |
US5453270A (en) | 1992-03-30 | 1995-09-26 | Hypermetabolic Therapies, Inc. | Pharmaceutical composition and method for hypermetabolic weight loss |
GB9209076D0 (en) | 1992-04-27 | 1992-06-10 | Ici Plc | Chemical compounds |
AU4543193A (en) | 1992-06-22 | 1994-01-24 | Henry E. Young | Scar inhibitory factor and use thereof |
WO1995006411A1 (en) | 1993-08-30 | 1995-03-09 | Lipocyte, Inc. | Method and composition for weight reduction |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
US5837670A (en) | 1995-04-18 | 1998-11-17 | Hartshorn; Richard Timothy | Detergent compositions having suds suppressing properties |
FR2733513B1 (fr) | 1995-04-25 | 1997-07-18 | Centre Nat Rech Scient | Lignees immortalisees de cellules issues du tissu adipeux humain, leur procede de preparation et leurs applications |
US5789654A (en) | 1996-05-09 | 1998-08-04 | Beth Israel Hospital Association | Transgenic animals deficient in endogenous β3 -adrenergic receptor and uses thereof |
US6246912B1 (en) | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
IT1286236B1 (it) | 1996-09-24 | 1998-07-08 | Galaxy Top International Spa | Procedimento per la stimolazione controllata di regioni predefinite del corpo umano tramite l'applicazione di segnali elettrici variabili |
EP0885008B1 (en) | 1996-09-30 | 2009-12-30 | Dennis Jones | The regulation of body weight with materials derived from citrus varieties |
US6224873B1 (en) | 1996-09-30 | 2001-05-01 | Zhishin, Llc | Regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
WO1998031396A1 (en) | 1997-01-15 | 1998-07-23 | Duke University | Respiration uncoupling protein |
WO1998045313A1 (en) | 1997-04-04 | 1998-10-15 | Amylin Pharmaceuticals, Inc. | Novel uncoupling protein and methods of use |
JP2001526538A (ja) | 1997-05-07 | 2001-12-18 | ノバルティス アクチエンゲゼルシャフト | 脱共役タンパク質相同物:ucp3 |
US6426411B1 (en) | 1997-05-30 | 2002-07-30 | Dana-Farber Cancer Institute | PGC-1, a novel brown fat pparγ coactivator |
US5911992A (en) | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
SE9702457D0 (sv) | 1997-06-26 | 1997-06-26 | Pharmacia & Upjohn Ab | Screening |
US6072100A (en) | 1998-01-28 | 2000-06-06 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
BR9815088B1 (pt) | 1998-02-05 | 2010-12-14 | equipamento de sonificaÇço de ultra-som. | |
DE19815411A1 (de) | 1998-04-06 | 1999-10-07 | Solvay Pharm Gmbh | Thermogenese stimulierend wirksame Arzneimittel |
WO2000004037A1 (en) | 1998-07-14 | 2000-01-27 | Amylin Pharmaceuticals, Inc. | Uncoupling protein 4 (ucp-4) and methods of use |
US7599736B2 (en) | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
EP1109594B1 (en) | 1998-08-31 | 2004-10-27 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport device comprising blades |
US6605297B2 (en) | 1998-09-01 | 2003-08-12 | Janiftec, Inc. | Substances having antiobese and visceral fat-reducing functions and utilization thereof |
US6532286B1 (en) | 1998-12-23 | 2003-03-11 | At&T Corp. | Method and system for processing a telephone call |
FR2788438B1 (fr) | 1999-01-14 | 2003-10-03 | Arkopharma Laboratoires | Composition pour le traitement de l'obesite et procede de traitement esthetique |
US6197580B1 (en) | 1999-02-01 | 2001-03-06 | American Home Products Corporation | Transcriptional regulation of the human β3-adrenergic receptor gene |
EP1172113A4 (en) | 1999-04-16 | 2004-06-30 | Sumitomo Pharma | MEDICINE FOR AUTONOMOUS NEUROPATHIES |
JP3207823B2 (ja) | 1999-04-28 | 2001-09-10 | リノール油脂株式会社 | 共役リノール酸を有効成分とする褐色脂肪増加剤 |
US7060437B1 (en) | 1999-05-05 | 2006-06-13 | Ohio University | Growth hormone-regulatable brown adipose tissue genes and proteins and uses thereof |
JP4155669B2 (ja) | 1999-06-14 | 2008-09-24 | 独立行政法人科学技術振興機構 | 植物の発熱関連遺伝子と発熱関連タンパク質 |
US6548739B2 (en) | 1999-06-18 | 2003-04-15 | City Of Hope | Method for activating peroxisome proliferator activated receptor-γ |
US6445955B1 (en) | 1999-07-08 | 2002-09-03 | Stephen A. Michelson | Miniature wireless transcutaneous electrical neuro or muscular-stimulation unit |
US6607500B2 (en) | 1999-07-08 | 2003-08-19 | Cyclotec Advanced Medical Technologies, Inc. | Integrated cast and muscle stimulation system |
US6381496B1 (en) | 1999-10-01 | 2002-04-30 | Advanced Bionics Corporation | Parameter context switching for an implanted device |
US6207878B1 (en) | 1999-10-21 | 2001-03-27 | University Of Iowa Research Foundation | Sarcospan-deficient mouse as a model for clinical disorders associated with sarcospan mutations |
US6983753B1 (en) | 1999-11-17 | 2006-01-10 | Smithkline Beecham Corporation | Infrared thermography |
JP4723707B2 (ja) | 1999-12-22 | 2011-07-13 | パナソニック電工株式会社 | 痩身器具 |
GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
JP2001259047A (ja) | 2000-03-22 | 2001-09-25 | Matsushita Seiko Co Ltd | 体脂肪燃焼方法 |
AU4929601A (en) | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
AU4928101A (en) | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Spiropiperidine derivatives as melanocortin receptor agonists |
US6475530B1 (en) | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
WO2002012887A2 (en) | 2000-08-08 | 2002-02-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of brown adipose cell disorders |
CA2419310A1 (en) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
WO2002032499A1 (en) | 2000-09-14 | 2002-04-25 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Method and apparatus to treat disorders of gastrointestinal peristalsis |
US6922590B1 (en) | 2000-11-21 | 2005-07-26 | Advanced Bionics Corporation | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion |
US7440806B1 (en) | 2000-11-21 | 2008-10-21 | Boston Scientific Neuromodulation Corp. | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion |
WO2002068619A2 (en) | 2001-01-22 | 2002-09-06 | Curagen Corporation | Bfit (brown fat inducible thioesterase) polypeptides and polynucleotides and their use |
US7169777B2 (en) | 2001-01-23 | 2007-01-30 | Eli Lilly And Company | Melanocortin receptor agonists |
US7157463B2 (en) | 2001-01-23 | 2007-01-02 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
JP2004523530A (ja) | 2001-01-23 | 2004-08-05 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体 |
EP1372653B1 (en) | 2001-02-28 | 2006-10-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
HUP0303376A3 (en) | 2001-02-28 | 2007-08-28 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof |
JP4316238B2 (ja) | 2001-02-28 | 2009-08-19 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体作動薬としてのアシル化ピペリジン誘導体 |
PT1385823E (pt) | 2001-04-09 | 2007-01-31 | Novartis Vaccines & Diagnostic | Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4) |
US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
JP2004533297A (ja) | 2001-05-29 | 2004-11-04 | メドトロニック・インコーポレーテッド | 心臓病の予防及び処置のための閉ループ神経調節システム |
EP1412374B1 (en) | 2001-07-05 | 2010-09-08 | Dana-Farber Cancer Institute, Inc. | Novel pgc-1 isoforms and uses therefor |
CA2453515A1 (en) | 2001-07-11 | 2003-01-23 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
ATE448481T1 (de) | 2001-07-17 | 2009-11-15 | Teijin Ltd | Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff |
WO2003007949A1 (en) | 2001-07-18 | 2003-01-30 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
US20070162085A1 (en) | 2001-07-23 | 2007-07-12 | Dilorenzo Biomedical, Llc | Method, apparatus, surgical technique, and stimulation parameters for autonomic neuromodulation for the treatment of obesity |
US20090118780A1 (en) | 2001-07-23 | 2009-05-07 | Dilorenzo Daniel John | Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
PL368977A1 (en) | 2001-08-08 | 2005-04-04 | Kevin R. Orton | Apparatus and method for electrically conductive weight reduction |
WO2003026576A2 (en) | 2001-09-24 | 2003-04-03 | Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College | Induction of brown adipocytes by transcription factor nfe2l2 |
US20030082168A1 (en) | 2001-10-22 | 2003-05-01 | Inna Yegorova | Compositions and methods for facilitating weight loss |
DE10294485T5 (de) | 2001-10-29 | 2004-04-29 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind |
EP1525323B1 (en) | 2001-11-09 | 2015-01-21 | Dana-Farber Cancer Institute, Inc. | Pgc-1beta, a novel pgc-1 homologue and uses therefor |
CN2520883Y (zh) | 2001-12-11 | 2002-11-20 | 中国人民解放军海军潜艇学院 | 电疗仪 |
CA2476873A1 (en) | 2002-02-20 | 2003-08-28 | Liposonix, Inc. | Ultrasonic treatment and imaging of adipose tissue |
JP4472996B2 (ja) | 2002-03-15 | 2010-06-02 | ザ・ジェネラル・ホスピタル・コーポレイション | 脂肪組織を選択的に破壊する医療装置を制御する方法 |
US7689277B2 (en) | 2002-03-22 | 2010-03-30 | Leptos Biomedical, Inc. | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
US7239912B2 (en) | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
AU2003228603A1 (en) | 2002-04-22 | 2003-11-10 | Rtc Research And Development, Llc. | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
US20040077566A9 (en) | 2002-05-09 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the treatment and diagnosis of body weight disorders |
US6565847B1 (en) | 2002-07-03 | 2003-05-20 | Vitacost.Com, Inc. | Thermogenic weight management composition |
US7236830B2 (en) | 2002-12-10 | 2007-06-26 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders |
US7025791B2 (en) | 2002-12-02 | 2006-04-11 | Gi Dynamics, Inc. | Bariatric sleeve |
WO2004063354A2 (en) | 2003-01-10 | 2004-07-29 | The Regents Of The University Of Michigan | Compositions and methods for characterizing and regulating wnt pathways |
US7160886B2 (en) | 2003-03-03 | 2007-01-09 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
CN1758891B (zh) | 2003-03-13 | 2012-10-10 | 自然美有限公司 | 脂肪团的超声处理 |
AU2004226452B2 (en) | 2003-03-26 | 2008-07-24 | Merck Sharp & Dohme Corp. | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists |
US7463928B2 (en) | 2003-04-25 | 2008-12-09 | Medtronic, Inc. | Identifying combinations of electrodes for neurostimulation therapy |
ES2329370T3 (es) | 2003-06-04 | 2009-11-25 | Nestec S.A. | Bebida para el control del peso. |
JP4231349B2 (ja) | 2003-07-02 | 2009-02-25 | 株式会社ディスコ | レーザー加工方法およびレーザー加工装置 |
US20050136429A1 (en) | 2003-07-03 | 2005-06-23 | Massachusetts Institute Of Technology | SIRT1 modulation of adipogenesis and adipose function |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050045498A1 (en) | 2003-08-25 | 2005-03-03 | Kimberly-Clark Worldwide, Inc. | Cold pack |
JP3951271B2 (ja) | 2003-09-30 | 2007-08-01 | 小林製薬株式会社 | 体脂肪燃焼促進剤 |
EP1677735B1 (en) | 2003-10-17 | 2014-07-23 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
WO2005040109A1 (en) | 2003-10-22 | 2005-05-06 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
US8620402B2 (en) | 2003-10-30 | 2013-12-31 | Halthion Medical Technologies, Inc. | Physiological sensor device |
KR100661118B1 (ko) | 2003-11-12 | 2006-12-26 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
EP1715790A2 (en) | 2004-02-11 | 2006-11-02 | Ethicon, Inc. | System and method for urodynamic evaluation utilizing micro-electronic mechanical system |
US8751003B2 (en) | 2004-02-11 | 2014-06-10 | Ethicon, Inc. | Conductive mesh for neurostimulation |
US8165695B2 (en) | 2004-02-11 | 2012-04-24 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
US7979137B2 (en) | 2004-02-11 | 2011-07-12 | Ethicon, Inc. | System and method for nerve stimulation |
US7647112B2 (en) | 2004-02-11 | 2010-01-12 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
US7691823B2 (en) | 2004-03-05 | 2010-04-06 | University Of Massachusetts | RIP140 regulation of glucose transport |
US7476406B1 (en) | 2004-05-17 | 2009-01-13 | Nse Products, Inc. | Multifaceted weight control system |
US20060014178A1 (en) | 2004-05-26 | 2006-01-19 | Whitson Robert H | Use of Mrf-2 for screening and therapies |
EP1761303B1 (en) | 2004-06-10 | 2011-09-07 | Medtronic Urinary Solutions, Inc. | Systems and methods for bilateral stimulation of left and right branches of the dorsal genital nerves to treat dysfunctions, such as urinary incontinence |
US20050288740A1 (en) | 2004-06-24 | 2005-12-29 | Ethicon Endo-Surgery, Inc. | Low frequency transcutaneous telemetry to implanted medical device |
HUP0401177A2 (en) | 2004-06-14 | 2007-09-28 | N Gene Res Lab Inc | Pharmaceutical composition for increasing the mitochondrial genesis |
US7599744B2 (en) | 2004-06-24 | 2009-10-06 | Ethicon Endo-Surgery, Inc. | Transcutaneous energy transfer primary coil with a high aspect ferrite core |
US7191007B2 (en) | 2004-06-24 | 2007-03-13 | Ethicon Endo-Surgery, Inc | Spatially decoupled twin secondary coils for optimizing transcutaneous energy transfer (TET) power transfer characteristics |
US7599743B2 (en) | 2004-06-24 | 2009-10-06 | Ethicon Endo-Surgery, Inc. | Low frequency transcutaneous energy transfer to implanted medical device |
US20060008540A1 (en) | 2004-07-08 | 2006-01-12 | Rulin Xiu | Herbal compositions comprising portaluca |
JP2008506696A (ja) | 2004-07-16 | 2008-03-06 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体作用薬としてのアシル化ピペリジン誘導体 |
CN1988906A (zh) | 2004-07-19 | 2007-06-27 | 默克公司 | 用作黑皮质素-4受体激动剂的酰基化哌啶衍生物 |
US20060084637A1 (en) | 2004-10-18 | 2006-04-20 | Maria Alemany | Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same |
DE102005000666B3 (de) | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20060204599A1 (en) | 2005-03-14 | 2006-09-14 | Wheat Jared R | Dietary supplement and method of using same |
CA2602292A1 (en) | 2005-03-15 | 2006-09-21 | The Regents Of The University Of California | Method and system for modulating energy expenditure and neurotrophic factors |
JP5114381B2 (ja) | 2005-03-31 | 2013-01-09 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
US7825098B2 (en) | 2005-04-04 | 2010-11-02 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating Necdin function |
US7300409B2 (en) | 2005-05-12 | 2007-11-27 | S.C. Johnson & Son, Inc. | Therapy patch |
US8588930B2 (en) | 2005-06-07 | 2013-11-19 | Ethicon, Inc. | Piezoelectric stimulation device |
EP1888102A4 (en) | 2005-06-10 | 2008-10-15 | Univ Louisiana State | MODULATION OF PERIPHERAL CLOCKS IN ADIPOSE TISSUE |
CA2615209A1 (en) | 2005-08-01 | 2007-02-08 | Pfizer Limited | Mc4r-ag0nists for the treatment of urinary tract dysfunction |
EP1912968A1 (en) | 2005-08-04 | 2008-04-23 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
WO2007026347A1 (en) | 2005-09-01 | 2007-03-08 | Power Paper Ltd | Double-sided patch |
CA2558653C (en) | 2005-09-08 | 2012-12-18 | Aloka Co., Ltd. | Computerized tomography device using x rays and image processing method |
US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CA2624031A1 (en) | 2005-09-30 | 2007-04-12 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
AU2006304305B2 (en) | 2005-10-18 | 2010-04-01 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US9061146B2 (en) | 2005-10-28 | 2015-06-23 | Medtronic, Inc. | Impedance-based bladder sensing |
US20070282318A1 (en) | 2006-05-16 | 2007-12-06 | Spooner Gregory J | Subcutaneous thermolipolysis using radiofrequency energy |
CN2899835Y (zh) | 2006-05-18 | 2007-05-16 | 陕西秦明医学仪器股份有限公司 | 植入式减肥刺激器 |
US20080262411A1 (en) | 2006-06-02 | 2008-10-23 | Dobak John D | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
US7264602B1 (en) | 2006-06-28 | 2007-09-04 | Longsworth Sheryl M | Bandage assembly |
US7623278B2 (en) | 2006-09-26 | 2009-11-24 | Xerox Corporation | MEMS Fabry-Perot inline color scanner for printing applications using stationary membranes |
US8469976B2 (en) | 2006-10-04 | 2013-06-25 | Ethicon Endo-Surgery, Inc. | Methods of organ reconfiguration |
US9074012B2 (en) | 2006-10-18 | 2015-07-07 | Dana-Farber Cancer Institute, Inc. | Molecular control of brown fat differentiation and energy expenditure |
US20080132962A1 (en) | 2006-12-01 | 2008-06-05 | Diubaldi Anthony | System and method for affecting gatric functions |
US20080138449A1 (en) | 2006-12-06 | 2008-06-12 | H3 Formulations Ltd. | Composition and method for supporting thermogenesis and lipid oxidation |
US8128576B2 (en) | 2006-12-07 | 2012-03-06 | Ethicon, Inc. | System and method for urodynamic evaluation utilizing micro electro-mechanical system technology |
US8175718B2 (en) | 2006-12-19 | 2012-05-08 | Ethicon, Inc. | Electrode patch and method for neurostimulation |
EP2066272A2 (en) | 2006-12-28 | 2009-06-10 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
JP2010516653A (ja) | 2007-01-18 | 2010-05-20 | ノボ・ノルデイスク・エー/エス | 肥満の治療に使用される新規ペプチド |
US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
US7815895B2 (en) | 2007-05-21 | 2010-10-19 | Tohoku University | Method for activating efferent sympathetic nerves innervating adipose tissues to improve obesity and symptoms associated therewith |
WO2009008991A2 (en) | 2007-07-06 | 2009-01-15 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Dna-pkcs modulates energy regulation and brain function |
US8103355B2 (en) | 2007-07-16 | 2012-01-24 | Invasix Ltd | Method and device for minimally invasive skin and fat treatment |
US20090024144A1 (en) | 2007-07-18 | 2009-01-22 | Zeiner Mark S | Hybrid endoscopic/laparoscopic device for forming serosa to serosa plications in a gastric cavity |
US20090081715A1 (en) | 2007-09-07 | 2009-03-26 | Cobalt Technologies, Inc., A Delaware Corporation | Engineered Light-Emitting Reporter Genes |
US9529972B2 (en) | 2007-09-24 | 2016-12-27 | Medtronic, Inc. | Patient event indication |
US8352026B2 (en) | 2007-10-03 | 2013-01-08 | Ethicon, Inc. | Implantable pulse generators and methods for selective nerve stimulation |
US8162530B2 (en) | 2007-10-05 | 2012-04-24 | Main Power Electrical Factory Ltd. | Handheld electric mixer |
US8260439B2 (en) | 2007-11-16 | 2012-09-04 | Ethicon, Inc. | Nerve stimulation patches and methods for stimulating selected nerves |
WO2009067501A2 (en) | 2007-11-19 | 2009-05-28 | Joslin Diabetes Center, Inc. | Infrared thermography for monitoring brown adipose tissue |
US20090149918A1 (en) | 2007-12-06 | 2009-06-11 | Peter Krulevitch | Implantable antenna |
JP5189654B2 (ja) | 2007-12-12 | 2013-04-24 | カーディアック ペースメイカーズ, インコーポレイテッド | 肺動脈から神経刺激を伝達する刺激システム |
US8170683B2 (en) * | 2007-12-14 | 2012-05-01 | Ethicon, Inc. | Dermatome stimulation devices and methods |
US8142452B2 (en) | 2007-12-27 | 2012-03-27 | Ethicon Endo-Surgery, Inc. | Controlling pressure in adjustable restriction devices |
WO2009097542A2 (en) | 2008-01-30 | 2009-08-06 | Board Of Regents Of The University Of Texas System | Ileal electrical stimulation |
US8114345B2 (en) | 2008-02-08 | 2012-02-14 | Ethicon Endo-Surgery, Inc. | System and method of sterilizing an implantable medical device |
US8057492B2 (en) | 2008-02-12 | 2011-11-15 | Ethicon Endo-Surgery, Inc. | Automatically adjusting band system with MEMS pump |
US20120040342A1 (en) | 2008-03-17 | 2012-02-16 | Geisinger Clinic | Genetic Indicators Of Weight Loss |
EP2334374A4 (en) | 2008-08-26 | 2011-12-28 | Janssen Biotech Inc | STIMULATING THE RELEASE OF A SATIETY HORMONE |
US7818060B2 (en) | 2008-10-31 | 2010-10-19 | Medtronic, Inc. | Determination of stimulation output capabilities throughout power source voltage range |
US7970478B2 (en) | 2008-12-19 | 2011-06-28 | Ethicon, Inc. | Optimizing stimulation therapy of an external stimulating device based on firing of action potential in target nerve |
US8897885B2 (en) | 2008-12-19 | 2014-11-25 | Ethicon, Inc. | Optimizing the stimulus current in a surface based stimulation device |
US8303982B2 (en) | 2009-03-20 | 2012-11-06 | Ethicon, Inc | Self-locating, multiple application, and multiple location medical patch systems and methods therefor |
US8340772B2 (en) | 2009-05-08 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Brown adipose tissue utilization through neuromodulation |
US20110000270A1 (en) | 2009-06-18 | 2011-01-06 | Organic Green Solutions, Inc. | Organic slurry compositions and method of application |
US8126530B2 (en) | 2009-10-26 | 2012-02-28 | Ethicon, Inc. | Offset electrode |
US20110144490A1 (en) | 2009-12-10 | 2011-06-16 | General Electric Company | Devices and methods for adipose tissue reduction and skin contour irregularity smoothing |
US9220885B2 (en) | 2009-12-18 | 2015-12-29 | Ethicon, Inc. | Placement devices that enable patients to accurately position medical patches at target locations and methods therefor |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
US20120165792A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
US20120172783A1 (en) | 2010-12-29 | 2012-07-05 | Ethicon Endo-Surgery, Inc. | Obesity therapy and heart rate variability |
US9381219B2 (en) | 2010-12-29 | 2016-07-05 | Ethicon Endo-Surgery, Inc. | Brown adipocyte modification |
WO2012092057A1 (en) | 2010-12-29 | 2012-07-05 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue with light |
US8696616B2 (en) | 2010-12-29 | 2014-04-15 | Ethicon Endo-Surgery, Inc. | Obesity therapy and heart rate variability |
WO2013115756A2 (en) | 2010-12-29 | 2013-08-08 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue with cooling |
WO2012092056A1 (en) | 2010-12-29 | 2012-07-05 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue with targeted substance delivery |
FR2972942B1 (fr) | 2011-03-21 | 2017-11-24 | Arkema France | Procede de fabrication de nanotubes de carbone et appareil pour la mise en oeuvre du procede. |
US8968377B2 (en) * | 2011-05-09 | 2015-03-03 | The Invention Science Fund I, Llc | Method, device and system for modulating an activity of brown adipose tissue in a vertebrate subject |
US9314609B2 (en) | 2011-10-28 | 2016-04-19 | Martin Brown | Device for providing electrical stimulation of a human knee |
JP2013126486A (ja) | 2011-12-19 | 2013-06-27 | Panasonic Corp | 電気刺激装置 |
US20130209418A1 (en) * | 2012-02-15 | 2013-08-15 | Johnson & Johnson Regenerative Therapeutics, Llc | Methods and composition related to brown adipose-like cells |
US8812100B2 (en) | 2012-05-10 | 2014-08-19 | Ethicon Endo-Surgery, Inc. | Device and method for self-positioning of a stimulation device to activate brown adipose tissue depot in a supraclavicular fossa region |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
-
2014
- 2014-12-29 US US14/584,046 patent/US10092738B2/en active Active
-
2015
- 2015-12-14 EP EP15828707.8A patent/EP3240606B1/en active Active
- 2015-12-14 JP JP2017553044A patent/JP6668379B2/ja active Active
- 2015-12-14 WO PCT/US2015/065513 patent/WO2016109169A1/en active Application Filing
- 2015-12-14 CN CN201580077109.8A patent/CN107278161B/zh active Active
- 2015-12-14 BR BR112017013892-1A patent/BR112017013892B1/pt not_active IP Right Cessation
-
2018
- 2018-08-22 US US16/108,132 patent/US10960201B2/en active Active
-
2021
- 2021-03-17 US US17/203,904 patent/US20210205608A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN107278161A (zh) | 2017-10-20 |
JP2018501069A (ja) | 2018-01-18 |
BR112017013892A2 (pt) | 2018-01-02 |
US20210205608A1 (en) | 2021-07-08 |
US10960201B2 (en) | 2021-03-30 |
CN107278161B (zh) | 2021-07-16 |
EP3240606B1 (en) | 2022-11-16 |
US10092738B2 (en) | 2018-10-09 |
EP3240606A1 (en) | 2017-11-08 |
WO2016109169A1 (en) | 2016-07-07 |
US20180369549A1 (en) | 2018-12-27 |
US20160184568A1 (en) | 2016-06-30 |
BR112017013892B1 (pt) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6668379B2 (ja) | 褐色脂肪組織を活性化する際に神経を阻害するための方法及び装置 | |
US10201695B2 (en) | Methods and devices for activating brown adipose tissue using electrical energy | |
US7702386B2 (en) | Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes | |
US20110238128A1 (en) | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes | |
US11679252B2 (en) | Methods and devices for activating brown adipose tissue using electrical energy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181011 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6668379 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |